Instapath

Instapath is pioneering a rapid, non-destructive digital pathology platform designed to provide immediate tissue analysis at the point of procedure. Its core technology, the Neo system, is a Class I medical device that uses patented fluorescence microscopy to image fresh tissue without traditional histology processing, saving hours or days in the diagnostic timeline. The company complements its hardware with the Luci imaging system for larger specimens and a remote scanning service (LuciNow), targeting a significant market opportunity in surgical margin assessment and intraoperative diagnostics. As a private, likely pre-revenue company, its success hinges on clinical adoption, regulatory pathways for expanded claims, and competition against established and emerging digital pathology solutions.

Patented fluorescence microscopy imaging for non-destructive, rapid digitization of fresh, fixed, or frozen tissue samples without cutting or fixing, preserving tissue for downstream testing.

Instapath competes with traditional frozen section analysis and established digital pathology scanner companies (e.g., Philips, Leica, 3DHISTECH). It also faces competition from other intraoperative imaging technologies like confocal microscopy (e.g., Caliber I.D.) and Raman spectroscopy. Its differentiation is the combination of speed, non-destructive sampling, and preservation of tissue for downstream analysis.